Drug Costs Are an Adherence Barrier — and Afinitor Is One of the Most Expensive

As a prescriber, you already know that the best treatment plan in the world doesn't work if patients can't afford to fill their prescriptions. With Afinitor (Everolimus), the cost barrier is especially steep — brand-name Afinitor runs approximately $18,400 to $19,260 per 28-day supply, and even with insurance, patients on specialty tiers can face coinsurance of 25–50%.

Financial toxicity is a well-documented driver of non-adherence in oncology. Patients skip doses, delay refills, or abandon treatment entirely because they can't manage the out-of-pocket burden. This guide provides a practical overview of the savings programs, generic alternatives, and cost-conversation strategies you and your team can use to keep patients on therapy.

What Patients Are Actually Paying

Understanding the financial landscape helps you anticipate which patients will need the most support:

• Brand-name Afinitor without insurance: $18,400–$19,260 per 28-day supply (approximately $220,000–$230,000 per year)
• Generic Everolimus without insurance: Ranges from $90 to $4,030 per 28-day supply depending on the pharmacy and discount card used
• Commercial insurance (specialty tier): Typical coinsurance of 25–50%, meaning patients may owe $4,600–$9,600 per month for brand-name before copay assistance
• Medicare Part D: Patients in the coverage gap ("donut hole") face 25% coinsurance on brand-name drugs; catastrophic coverage kicks in after $8,000 in out-of-pocket spending (2026)

Nearly all payers require prior authorization for Afinitor/Everolimus. Many also require step therapy documentation and specialty pharmacy dispensing. Your staff should be familiar with these requirements to avoid treatment delays.

Manufacturer Savings Programs

Novartis Oncology Universal Co-pay Program

This is the primary manufacturer copay assistance program for Afinitor:

• Eligibility: Commercially insured patients with a valid prescription for Afinitor
• Benefit: Eligible patients may pay as little as $0 out of pocket
• Annual cap: Up to $15,000 in copay assistance per calendar year
• Exclusions: Not available for patients on Medicare, Medicaid, Tricare, or other government-funded insurance
• Enrollment: Patients can enroll through their specialty pharmacy, through the Novartis website, or with help from your office staff

For commercially insured patients, this program alone can eliminate the out-of-pocket burden entirely in most cases. Make sure your team proactively offers enrollment rather than waiting for patients to ask.

Novartis Patient Assistance Foundation (NPAF)

For patients who are uninsured or cannot afford their medication even with insurance:

• Eligibility: Uninsured patients, or patients whose insurance does not adequately cover the cost
• Benefit: Afinitor provided free of charge
• Application: Available at pap.novartis.com or by calling 1-800-277-2254
• Documentation needed: Proof of income, insurance status, and a valid prescription

NPAF is especially important for Medicare patients who don't qualify for the copay program and face significant coinsurance.

Coupon and Discount Card Programs

For patients paying cash or whose insurance doesn't cover Everolimus adequately, third-party discount programs can provide significant savings on generic Everolimus:

• GoodRx / GoodRx Gold: Generic Everolimus as low as $90.54 per 28-day supply at participating pharmacies
• SingleCare: Competitive pricing on generic Everolimus at major chains
• RxSaver, Optum Perks, BuzzRx: Additional discount card options worth comparing

These programs work best for the generic formulation. Brand-name Afinitor is rarely discounted significantly through third-party cards because it's dispensed through specialty pharmacies with manufacturer contracts.

A good practice: have your team check 2-3 discount platforms when patients report cost barriers, as prices vary significantly by pharmacy and program.

Generic Alternatives and Therapeutic Substitution

Generic Everolimus

Generic Everolimus tablets are available from multiple manufacturers and are therapeutically equivalent to brand-name Afinitor. Key points for prescribers:

• Available in the same strengths as Afinitor tablets (2.5 mg, 5 mg, 7.5 mg, 10 mg)
• Significantly less expensive — from $90 to $4,030 per 28-day supply vs. $18,400+ for brand
• Same active ingredient, same mechanism of action, same FDA-approved indications
• Prescribe as "Everolimus" (not "Afinitor") to allow generic substitution unless there's a specific clinical reason to require the brand

Note: Afinitor Disperz (tablets for oral suspension) may not have a generic equivalent in all strengths. Verify availability for pediatric TSC patients who require the Disperz formulation.

Therapeutic Alternatives

When cost is prohibitive and generic Everolimus is still too expensive, consider whether a therapeutic alternative is clinically appropriate:

• Temsirolimus (Torisel) — IV mTOR inhibitor for advanced renal cell carcinoma. Different administration route but same drug class.
• Sunitinib (Sutent) — Tyrosine kinase inhibitor for PNET and renal cell carcinoma. Different mechanism but overlapping indications.
• Palbociclib (Ibrance) — CDK4/6 inhibitor for HR+/HER2- breast cancer. Different target but may be appropriate depending on treatment history.

Therapeutic substitution should always be based on clinical judgment, patient history, and available evidence — not cost alone. But when two options are clinically equivalent and one is financially feasible, that matters for adherence.

Building Cost Conversations Into Your Workflow

Financial discussions shouldn't happen only when patients report problems. By then, they may have already missed doses or abandoned treatment. Here's how to make cost a routine part of care:

At Prescribing

• Mention cost proactively: "Afinitor is an expensive medication, but there are programs that can help. Let me connect you with our financial counselor."
• Prescribe generic Everolimus by default unless there's a clinical reason for brand-name.
• Initiate copay assistance enrollment at the same time as prior authorization — don't make patients wait.

At Follow-Up

• Ask about affordability: "Have you had any trouble filling your prescription?" or "Is the cost manageable?"
• Watch for non-adherence signals: Missed refills, requests to delay labs, or skipping appointments can indicate financial strain.
• Re-check eligibility annually: Insurance changes, income changes, and program renewals can affect access to savings programs.

Empower Your Staff

• Train nursing staff and medical assistants to initiate financial assistance applications
• Keep a reference sheet of current Afinitor savings programs in your office
• Designate a team member (nurse navigator, social worker, or financial counselor) as the point person for specialty drug affordability

Leverage Your Specialty Pharmacy

Specialty pharmacies that dispense Afinitor often have dedicated patient support teams that can:

• Verify insurance coverage and copay amounts before filling
• Enroll patients in manufacturer copay programs
• Connect patients with foundation grants and charitable assistance
• Coordinate refills and delivery schedules

Build a relationship with the specialty pharmacy your patients use most frequently. They can be an extension of your care team for the financial side of treatment.

Resources for Your Practice

• Novartis copay program: Enroll through specialty pharmacy or Novartis website
• Novartis Patient Assistance (NPAF): pap.novartis.com | 1-800-277-2254
• GoodRx generic pricing: goodrx.com/everolimus
• Medfinder for providers: medfinder.com/providers — help patients find pharmacies with Afinitor in stock
• Patient-facing savings guide: How to Save Money on Afinitor — share this link with patients

Final Thoughts

The financial burden of Afinitor is real, but it's also addressable. Between manufacturer copay programs, patient assistance foundations, generic Everolimus, and third-party discount cards, most patients can find a path to affordable treatment. The key is making cost conversations a standard part of your prescribing workflow — not an afterthought.

When you integrate financial support into the treatment plan from day one, you improve adherence, outcomes, and the patient experience. For more clinical resources and to help patients locate Afinitor in stock, visit Medfinder for Providers.